Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ACP3 | P15309 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.46 |
| ▸ | KMO | O15229 | 1/20 | 0.46 |
| ▸ | GRM8 | O00222 | 1/20 | 0.45 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7349213 | 1.00 | POLB (0.51) | POLBL3MBTL1HTTSMN1; SMN2ACP3 | |
| SCHEMBL6903563 | 1.00 | POLB (0.51) | POLBL3MBTL1HTTSMN1; SMN2ACP3 | |
| SCHEMBL8125876 | 1.00 | POLB (0.51) | POLBL3MBTL1HTTSMN1; SMN2ACP3 | |
| SCHEMBL16933041 | 0.91 | ACP3 (0.54) | POLBL3MBTL1HTTSMN1; SMN2ACP3 | |
| SCHEMBL10876371 | 0.85 | FFAR1 (0.49) | POLBL3MBTL1HTTSMN1; SMN2ACP3 | |
| SCHEMBL6905899 | 0.85 | MEN1 (0.50) | L3MBTL1HTTSMN1; SMN2FFAR1MEN1 | |
| SCHEMBL6903550 | 0.85 | MEN1 (0.50) | L3MBTL1HTTSMN1; SMN2FFAR1MEN1 | |
| SCHEMBL3060638 | 0.84 | L3MBTL1 (0.51) | L3MBTL1HTTSMN1; SMN2ACP3MEN1 | |
| SCHEMBL7267166 | 0.83 | FNTA (0.47) | POLBL3MBTL1HTTSMN1; SMN2ACP3 | |
| SCHEMBL21200270 | 0.82 | MEN1 (0.57) | POLBL3MBTL1HTTSMN1; SMN2ACP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1015441-B1 | PROCESS TO PRODUCE 4-HYDROXY-2-OXO-PYRANE DERIVATIVES USEFUL AS PROTEASE INHIBITORS | UPJOHN CO (US) | 2004-05-12 | — | — | EP | claimed |
| CN-100471832-C | Process to produce a protease inhibitor | PHARMACIA & UPJOHN CO LLC (US) | 2009-03-25 | — | — | CN | disclosed |
| US-20090062346-A1 | DEUTERIUM-ENRICHED TIPRANAVIR | PROTIA, LLC (US) | 2009-03-05 | — | — | US | disclosed |
| CN-1990452-A | Process to produce a protease inhibitor | UPJOHN CO (US) | 2007-07-04 | — | — | CN | disclosed |
| CN-1298714-C | Novel process for preparing 4-hydroxy-2-oxo-pyran derivatives as protease inhibitors | UPJOHN CO (US) | 2007-02-07 | — | — | CN | disclosed |
| CN-1284763-C | Novel intemediate for preparing 4-hydroxy-2-oxygen-pyran derivatives as protease inhibitor | PHARMACIA & UPJOHN CO LLC (US) | 2006-11-15 | — | — | CN | disclosed |
| CN-1511820-A | Novel intemediate for preparing 4-hydroxy-2-oxygen-pyran derivatives as protease inhibitor | �������Ŷ���Լ��������˾ | 2004-07-14 | — | — | CN | disclosed |
| EP-0682663-B1 | 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS | UPJOHN CO (US) | 2001-04-18 | — | — | EP | disclosed |
| CN-1268947-A | Novel process for preparing 4-hydroxy-2-oxo-pyran derivatives as protease inhibitors | UPJOHN CO (US) | 2000-10-04 | — | — | CN | disclosed |
| EP-1015441-A1 | PROCESS TO PRODUCE 4-HYDROXY-2-OXO-PYRANE DERIVATIVES USEFUL AS PROTEASE INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 2000-07-05 | — | — | EP | disclosed |
| WO-1999012919-A1 | PROCESS TO PRODUCE 4-HYDROXY-2-OXO-PYRANE DERIVATES USEFUL AS PROTEASE INHIBITORS | PHARMACIA & UPJOHN COMPANY (US) | 1999-03-18 | — | — | WO | disclosed |
| US-5686486-A | 4-hydroxy-benzopyran-2-ones and 4-hydroxy-cycloalkyl b!pyran-2-ones useful to treat retroviral infections | PHARMACIA & UPJOHN COMPANY (US) | 1997-11-11 | — | — | US | disclosed |
| EP-0682663-A1 | 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 1995-11-22 | — | — | EP | disclosed |
| WO-1994018188-A1 | 4-HYDROXY-BENZOPYRAN-2-ONES AND 4-HYDROXY-CYCLOALKYL[B]PYRAN-2-ONES USEFUL TO TREAT RETROVIRAL INFECTIONS | THE UPJOHN COMPANY (US) | 1994-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062346-A1 | DEUTERIUM-ENRICHED TIPRANAVIR | SAMHD1, NSD3, NSD1 | POLB 397/4885L3MBTL1 3075/4885HTT 194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.